1e
19
1
49
2
2
18
1b
1d
18
31
3d
1d
2 29
1d
25
Alain H. Rook, M.D.
78
3d
Professor of Dermatology
7
62
Department: Dermatology
4
1
b
1d
46
Contact information
47
4
3
3
3
2
4
b
1f
47
Department of Dermatology
23 3400 Civic Center Boulevard
2d Perelman Center for Advanced Medicine
3c Philadelphia, Pa. 19104
Philadelphia, PA 19104
26
23 3400 Civic Center Boulevard
2d Perelman Center for Advanced Medicine
3c Philadelphia, Pa. 19104
Philadelphia, PA 19104
2e
Office: 215-662-7610
32 Fax: 215-349-8173
24
f
32 Fax: 215-349-8173
24
13
Education:
21 9 B.A. 14 (Biology) c
2c Brandeis University, 1971.
21 9 M.D. 15 (Medicine) c
2f University of Michigan, 1975.
c
3
3
3
3
8a
Permanent link21 9 B.A. 14 (Biology) c
2c Brandeis University, 1971.
21 9 M.D. 15 (Medicine) c
2f University of Michigan, 1975.
c
2 29
21
1e
1d
24
2b
29
27
23
1b4 Nihal M, Wu J, Stonesifer CJ, Daniels J, Choi J, Geskin L, Rook AH, Wood GS.: Epigenetic Regulation of Apoptosis in Cutaneous T-Cell Lymphoma: Implications for Therapy with Methotrexate, Jak Inhibitors, and Resveratrol. J Invest Dermatol. 142(2): 493-496, February 2022 Notes: doi: 10.1016/j.jid.2021.06.034. Epub 2021 Aug 3.PMID: 34358529 No abstract available.
148 Lewis DJ, Rook AH.: Combination therapies for mycosis fungoides/Sézary syndrome: biologic rationale and recommendations. Int J Dermatol. 60(9): e362-e364, September 2021 Notes: doi: 10.1111/ijd.15436. Epub 2021 Feb 9.PMID: 33559132 No abstract available.
18b Lewis DJ, Haun PL, Samimi SS, Vittorio CC, Villasenor-Park J, Barta SK, Landsburg DJ, Svoboda J, Nasta SD, Schuster SJ, Rook AH, Kim EJ.: Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome. JAMA Dermatol. 157(3): 317-321, March 2021 Notes: doi: 10.1001/jamadermatol.2020.4901.PMID: 33377934 Free PMC article.
13a Kim EJ, Kim YH, Rook AH, Lerner A, Duvic M, Reddy S, Robak T, Becker JC: Clinically significant responses achieved with romidespsin across disease compartments in patients with cutaneous T-cell lymphoma. Leuk Lymphoma (20), 1-22, March 2015.
168 Kim EJ, Kim YH, Rook AH, Lerner A, Duvic M, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Waksman J, Whittaker S.: Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. Leuk Lymphoma 20: 1-22, March 2015.
140 Cedeno-Laurent F, Singer Em, Wysocka M, Benoit BM, Vittorio CC, Kim EJ, Yosipovitch G, Rook AH.: Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. Clin Immunol 158(1): 1-7, March 2015.
130 Spaccarelli N, Gharavi M, Saboury B, Cheng G, Rook AH, Alavi A.: Role of (18)F-fluorodeoxyglucose positron emission tomography imaging in the management of primary cutaneous lymphomas. Hell J Nucl Med 17(2): 78-84, May-August 2014.
145 Wysocka M, Kossenkov AV, Benoit BM, Troxel AB, Singer E, Schaffer A, Kim B, Dentchev T, Nagata S, Ise T, Showe LC, Rook AH.: CD164 and FCRL3 are highly expressed on the CD4+CD26- T-cells in Sezary Syndrome patients. J Invest Dermatol 134: 229-36, 2014.
106 Samimi S, Chu E, Seykora J, Loren A, Vittorio C, Rook A, Rosenbach M, Kim EJ.: Dasatinib-induced leukotrichia in a patient with chronic myelogenous leukemia. JAMA Dermatol 149(5), May 2013.
2c
7
1d
1f
Selected Publications
179 Weiner DM, Clark AK, Bhansali RS, Pappas-Taffer L, Barta SK, Villasenor-Park J, Haun PL, Vittorio CC, Rook AH, Kim EJ, Samimi SS.: Usage and safety of topical tacrolimus in patients with mycosis fungoides. Clin Exp Dermatol. March 2022 Notes: doi: 10.1111/ced.15162. Online ahead of print.PMID: 35245947.1b4 Nihal M, Wu J, Stonesifer CJ, Daniels J, Choi J, Geskin L, Rook AH, Wood GS.: Epigenetic Regulation of Apoptosis in Cutaneous T-Cell Lymphoma: Implications for Therapy with Methotrexate, Jak Inhibitors, and Resveratrol. J Invest Dermatol. 142(2): 493-496, February 2022 Notes: doi: 10.1016/j.jid.2021.06.034. Epub 2021 Aug 3.PMID: 34358529 No abstract available.
148 Lewis DJ, Rook AH.: Combination therapies for mycosis fungoides/Sézary syndrome: biologic rationale and recommendations. Int J Dermatol. 60(9): e362-e364, September 2021 Notes: doi: 10.1111/ijd.15436. Epub 2021 Feb 9.PMID: 33559132 No abstract available.
18b Lewis DJ, Haun PL, Samimi SS, Vittorio CC, Villasenor-Park J, Barta SK, Landsburg DJ, Svoboda J, Nasta SD, Schuster SJ, Rook AH, Kim EJ.: Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome. JAMA Dermatol. 157(3): 317-321, March 2021 Notes: doi: 10.1001/jamadermatol.2020.4901.PMID: 33377934 Free PMC article.
13a Kim EJ, Kim YH, Rook AH, Lerner A, Duvic M, Reddy S, Robak T, Becker JC: Clinically significant responses achieved with romidespsin across disease compartments in patients with cutaneous T-cell lymphoma. Leuk Lymphoma (20), 1-22, March 2015.
168 Kim EJ, Kim YH, Rook AH, Lerner A, Duvic M, Reddy S, Robak T, Becker JC, Samtsov A, McCulloch W, Waksman J, Whittaker S.: Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma. Leuk Lymphoma 20: 1-22, March 2015.
140 Cedeno-Laurent F, Singer Em, Wysocka M, Benoit BM, Vittorio CC, Kim EJ, Yosipovitch G, Rook AH.: Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. Clin Immunol 158(1): 1-7, March 2015.
130 Spaccarelli N, Gharavi M, Saboury B, Cheng G, Rook AH, Alavi A.: Role of (18)F-fluorodeoxyglucose positron emission tomography imaging in the management of primary cutaneous lymphomas. Hell J Nucl Med 17(2): 78-84, May-August 2014.
145 Wysocka M, Kossenkov AV, Benoit BM, Troxel AB, Singer E, Schaffer A, Kim B, Dentchev T, Nagata S, Ise T, Showe LC, Rook AH.: CD164 and FCRL3 are highly expressed on the CD4+CD26- T-cells in Sezary Syndrome patients. J Invest Dermatol 134: 229-36, 2014.
106 Samimi S, Chu E, Seykora J, Loren A, Vittorio C, Rook A, Rosenbach M, Kim EJ.: Dasatinib-induced leukotrichia in a patient with chronic myelogenous leukemia. JAMA Dermatol 149(5), May 2013.
2c